32 year old female with on and off jaundice with abdominal distention with direct bilirubenemia diagnosed as cml,with chronic liver disease with hilar stricture with elevated total immunoglobulins level with tumor thrombosis of the portal vein what could be the probable diagnosis
Reading File
Finding Sources
Finding Sources
Finding Sources
Searching PubMed
IgG4 related disease cholangiopathy portal vein thrombosis liver
Finding Sources
Finding Sources
Finding Sources
Searching PubMed
IgG4 related sclerosing cholangitis diagnosis biliary stricture
Reading File
Reading File
Reading Article
Finding Sources
Finding Sources
Searching the Web
IgG4 related disease portal vein thrombosis hilar stricture CML diagnosis
I now have sufficient information to synthesize a comprehensive clinical answer. Let me compile it.
Clinical Analysis: Probable Diagnosis
This is a fascinating and complex clinical constellation. The key features that need to be unified:
| Feature | Significance |
|---|---|
| 32-year-old female | Young, atypical for most biliary malignancies |
| Intermittent jaundice | Cholestatic pattern, biliary obstruction |
| Abdominal distension | Hepatomegaly, ascites, or organomegaly |
| Direct (conjugated) bilirubinemia | Extrahepatic/intrahepatic cholestasis |
| Diagnosed with CML | Myeloproliferative neoplasm |
| Chronic liver disease | Parenchymal involvement |
| Hilar stricture | Involves the biliary confluence |
| Elevated total immunoglobulins | Polyclonal hypergammaglobulinemia |
| Tumor thrombosis of the portal vein | Malignant or inflammatory thrombosis |
The Unifying Diagnosis: IgG4-Related Disease (IgG4-RD) with IgG4-Related Sclerosing Cholangitis (IgG4-SC)
This is the most probable single unifying diagnosis that explains virtually all findings.
Why IgG4-RD/IgG4-SC fits:
1. Hilar Stricture + Elevated Immunoglobulins
IgG4-SC is the biliary manifestation of IgG4-RD — a systemic fibroinflammatory condition characterized by infiltration of organs by IgG4-positive plasma cells and frequently elevated serum IgG4 (~80% of cases at diagnosis). The biliary strictures in IgG4-SC can mimic perihilar cholangiocarcinoma (Klatskin tumor) almost exactly — this is one of the most recognized diagnostic pitfalls in hepatobiliary medicine. A 2026 case report (Yang Y et al., Front Immunol 2026) documented IgG4-SC presenting identically to perihilar cholangiocarcinoma with jaundice and hilar stricture, only confirmed after histopathology showed storiform fibrosis and IgG4-positive plasma cell infiltration.
"IgG4-related sclerosing cholangitis (IgG4-SC) is the biliary manifestation of IgG4-RD, a systemic disease characterized by infiltration of organs/tissues by IgG4-positive plasma cells and frequently elevated serum IgG4." — Yamada's Textbook of Gastroenterology, 7th ed.
2. Chronic Liver Disease + Direct Bilirubinemia
The chronic cholestasis from biliary obstruction at the hilum leads to secondary biliary cirrhosis and conjugated hyperbilirubinemia. IgG4-RD can also cause direct hepatic parenchymal involvement (IgG4-related hepatitis/hepatopathy), adding to chronic liver disease.
3. Portal Vein "Tumor" Thrombosis
This is critically important: in IgG4-RD, extensive periportal fibroinflammatory masses can encase the portal vein, producing what appears on imaging as tumor thrombus — but is actually inflammatory/fibrotic tissue. This can be misread as malignant tumor thrombosis. The fibroinflammatory infiltrate in IgG4-RD is known to cause vascular involvement and compression.
4. CML Co-diagnosis
Myeloproliferative neoplasms (MPNs) like CML are an independent risk factor for portal vein thrombosis — so the portal vein thrombosis in this patient may have a dual etiology: both the IgG4-inflammatory mass effect AND the hypercoagulable state from CML. IgG4-RD has also been reported in association with hematologic malignancies.
5. Abdominal Distension
Consistent with hepatosplenomegaly (from CML + cholestatic liver disease), ascites from portal hypertension (secondary to portal vein thrombosis + chronic liver disease), or retroperitoneal IgG4-related fibrosis.
Differential Diagnoses to Consider
| Diagnosis | For | Against |
|---|---|---|
| Cholangiocarcinoma (Klatskin tumor) | Hilar stricture, portal vein involvement | Young female, elevated immunoglobulins, may respond to steroids |
| Primary Sclerosing Cholangitis (PSC) | Biliary stricturing, cholestasis | PSC rarely has elevated IgG4, not associated with CML |
| Autoimmune Hepatitis | Young female, elevated Ig, chronic liver disease | Does not explain hilar stricture |
| Hepatocellular carcinoma with PVT | Portal vein thrombosis, chronic liver disease | Uncommon at 32, doesn't explain hilar stricture + high Ig |
| Lymphoma (biliary involvement from CML transformation) | CML known, portal infiltration possible | Less likely to elevate total Ig, less likely to cause hilar stricture specifically |
| Secondary Sclerosing Cholangitis | Hilar stricture, chronic disease | Needs identifiable cause |
Key Distinguishing Point: IgG4-SC vs. Cholangiocarcinoma
This distinction is clinically urgent because one is steroid-responsive and the other requires surgery/oncological treatment. The diagnostic approach involves:
- Serum IgG4 level (>2× upper limit of normal is highly specific for IgG4-SC)
- IgG4:IgG ratio in serum
- Cross-sectional imaging (MRI/MRCP): look for diffuse bile duct thickening vs. mass lesion
- Tissue biopsy — gold standard; shows storiform fibrosis + IgG4-positive plasma cells (>10/HPF on IHC)
- Trial of corticosteroids (if diagnosis likely): dramatic response supports IgG4-SC
- CA 19-9: marked elevation favors malignancy
"Patients with IgG4-SC present with cholangiographic features resembling PSC... IgG4-SC is rarely associated with IBD (~2%)... patients with IgG4-SC respond to immunosuppressive drugs." — Yamada's Textbook of Gastroenterology, 7th ed.
Summary
The most probable unifying diagnosis is IgG4-Related Disease, specifically:
- IgG4-Related Sclerosing Cholangitis → causing hilar stricture, jaundice, direct bilirubinemia
- IgG4-Related Hepatopathy → chronic liver disease
- Periportal IgG4 fibroinflammatory mass → portal vein tumor-like thrombosis/compression
- Polyclonal hypergammaglobulinemia → elevated total immunoglobulins (IgG4 subtype)
The CML is likely a co-existing hematologic condition that compounds the portal vein thrombosis through a hypercoagulable mechanism.
Immediate workup recommended: Serum IgG4 level, IgG subclasses, MRCP, liver biopsy with IHC for IgG4, and bone marrow assessment to confirm CML phase. If IgG4-SC confirmed, corticosteroids (prednisolone 0.6 mg/kg/day) can be dramatically effective and would avoid unnecessary surgical resection.
Sources:
- Yamada's Textbook of Gastroenterology, 7th ed. — IgG4-SC section
- Goldman-Cecil Medicine — Autoimmune hepatitis
- Robbins & Kumar Basic Pathology — Sclerosing cholangitis
- Yang Y et al. Front Immunol 2026 [PMID: 42079574] — IgG4-SC mimicking perihilar cholangiocarcinoma
Generate a quick reference protocol for IgG4-SC workup (labs, imaging, biopsy)
Reading File
Finding Sources
Finding Sources
Searching PubMed
IgG4 sclerosing cholangitis diagnosis guidelines criteria
Finding Sources
Finding Sources
Searching PubMed
IgG4 related sclerosing cholangitis workup diagnosis 2022
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
I have all the information needed. Here is the quick reference protocol:
IgG4-Related Sclerosing Cholangitis (IgG4-SC) — Quick Reference Workup Protocol
Diagnostic framework based on the HISORt criteria (Mayo Clinic / International Consensus): Histology · Imaging · Serology · Other organ involvement · Response to therapy
STEP 1 — SEROLOGY
| Test | Threshold | Interpretation |
|---|---|---|
| Serum IgG4 | > 2× ULN (>280 mg/dL) | Highly supportive; ~66–80% sensitivity |
| Serum IgG4 | > 4× ULN | 100% specific for IgG4-SC vs PSC |
| IgG subclasses (IgG1–4) | IgG4 subclass dominance | Confirms subclass elevation |
| Total IgG / total immunoglobulins | Elevated polyclonally | Seen in IgG4-RD, AIH overlap |
| ANA / ASMA | Usually negative | Helps exclude autoimmune hepatitis |
| AMA (anti-mitochondrial Ab) | Negative | Excludes PBC |
| CA 19-9 | Normal/mildly elevated | Markedly high → favors cholangiocarcinoma |
| LFTs | Cholestatic pattern (↑ALP, ↑GGT, ↑direct bili, mildly ↑ALT) | Typical for IgG4-SC |
| CBC, peripheral blood smear | Assess for myeloproliferative disease | Relevant if CML co-exists |
⚠️ Serum IgG4 can be normal in up to 30% of IgG4-SC — a negative result does NOT exclude the diagnosis.
STEP 2 — IMAGING
First-line
| Modality | Key Findings |
|---|---|
| Ultrasound (RUQ) | Bile duct wall thickening, hilar obstruction, hepatomegaly |
| MRCP | Biliary strictures; diffuse or segmental bile duct narrowing mimicking PSC; no upstream dilatation if inflammatory vs malignant mass |
| CT abdomen with contrast | Pancreatic enlargement + capsule sign (hypoechoic rim = highly specific for AIP/IgG4-RD); hilar soft tissue mass; portal vein involvement |
Second-line / Confirmatory
| Modality | Key Findings |
|---|---|
| ERCP | Direct visualization of strictures; allows brush cytology to exclude malignancy; can decompress obstructed biliary system |
| Intraductal ultrasound (IDUS) | Smooth outer margin, homogeneous wall thickening → IgG4-SC; irregular outer margin → malignancy |
| PET-CT (FDG) | Diffuse FDG uptake in bile ducts + pancreas + other organs → IgG4-RD; focal intense uptake → suspect malignancy |
Cholangiographic Classification of IgG4-SC (Nakazawa Classification)
- Type 1 — Lower bile duct only
- Type 2 — Diffuse intrahepatic + extrahepatic
- Type 3 — Hilar + lower bile duct (mimics Klatskin tumor most closely)
- Type 4 — Hilar only
STEP 3 — BIOPSY / HISTOPATHOLOGY
Required when serology and imaging remain inconclusive, or when malignancy cannot be excluded.
Biopsy Options (in order of invasiveness)
| Approach | Yield | Comments |
|---|---|---|
| Major papilla / bile duct pinch biopsy (endoscopic) | Good | >20 IgG4+ plasma cells/HPF on IHC is diagnostic |
| EUS-guided fine needle biopsy | Moderate–good | Preferred if pancreatic mass present |
| Percutaneous liver biopsy | Good for hepatic parenchymal disease | |
| Surgical excision / choledochotomy | Definitive | Reserve for failed endoscopic approaches |
Four Cardinal Histopathologic Features of IgG4-RD
- Lymphoplasmacytic infiltrate — dense IgG4-positive plasma cells
- Storiform (cartwheel) fibrosis — whorled fibroblast pattern
- Obliterative phlebitis — inflammatory occlusion of veins
- IgG4+ plasma cells ≥ 10/HPF on immunohistochemistry (IHC)
Type 1 AIP/IgG4-SC: IgG4 tissue staining abundant (≥10 cells/hpf). IgG4:IgG ratio >40% on IHC strengthens diagnosis.
STEP 4 — OTHER ORGAN INVOLVEMENT
Screen for multiorgan IgG4-RD (present in ~90% of IgG4-SC patients):
| Organ | Manifestation | Investigation |
|---|---|---|
| Pancreas | Type 1 AIP (most common, ~90%) | CT/MRI pancreas |
| Salivary glands | Bilateral submandibular enlargement | Clinical exam, USS |
| Kidneys | IgG4-related tubulointerstitial nephritis | Renal function, CT |
| Retroperitoneum | Retroperitoneal fibrosis | CT/MRI |
| Lungs | IgG4-related pulmonary disease | HRCT chest |
| Orbital/lacrimal glands | Dacryoadenitis, proptosis | Slit-lamp, CT orbits |
| Lymph nodes | Generalized lymphadenopathy | CT |
| Portal vein | Periportal inflammatory mass / apparent tumor thrombosis | CT/MRI with contrast |
STEP 5 — STEROID TRIAL (Diagnostic + Therapeutic)
Indicated when IgG4-SC is likely but histology not yet available, OR as a confirmatory step:
| Parameter | Detail |
|---|---|
| Drug | Prednisolone (prednisone) |
| Initial dose | 0.6 mg/kg/day (typically 30–40 mg/day) |
| Duration | 4 weeks at full dose |
| Taper | Reduce by 5 mg/week based on clinical response |
| Monitor | LFTs, serum IgG4, bilirubin, MRCP at 4–8 weeks |
| Expected response | Dramatic improvement in 2–4 weeks (>95% respond) |
| Poor response | Raises strong suspicion for cholangiocarcinoma — reassess urgently |
STEP 6 — LONG-TERM MANAGEMENT
| Scenario | Approach |
|---|---|
| Remission achieved | Steroid taper; consider azathioprine 2 mg/kg/day or mycophenolate mofetil for maintenance |
| Relapse (occurs in 20–60% of Type 1) | Re-treat with steroids; add immunomodulator |
| Multiple relapses | Rituximab (B-cell depletion) — most effective for refractory disease |
| Cirrhosis or biliary complications | Endoscopic stenting + hepatology referral |
| Long-term prognosis | Excellent if treated; cirrhosis and cholangiocarcinoma are rare outcomes |
Diagnostic Confidence Levels (HISORt-based)
| Level | Criteria Met |
|---|---|
| Definitive | Histology + ≥1 other feature |
| Probable | Imaging + serology + other organ involvement |
| Possible | Imaging alone OR serology alone + steroid response |
| Exclude | Poor steroid response + CA 19-9 markedly elevated → pursue malignancy workup |
Key pitfall: IgG4-SC can present identically to perihilar cholangiocarcinoma (Klatskin tumor) — IgG4 levels can even be initially normal in some cases (postoperative elevation reported). Integration of all five HISORt domains — not serology alone — is mandatory before committing to surgery.
Sources: Sleisenger & Fordtran's GI and Liver Disease; Harrison's Principles of Internal Medicine 22e (2025); Yamada's Textbook of Gastroenterology, 7th ed.; Yang Y et al., Front Immunol 2026 [PMID: 42079574]
15 year old female with short stature with anemia with tanner stage 0 evaluation and anemia causes
Finding Sources
Finding Sources
Finding Sources
Searching PubMed
short stature delayed puberty anemia adolescent female evaluation
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Your credits are exhausted. Your daily credits reset tomorrow, or you can purchase a top-up for more.
Create a diagnostic flowchart PDF for delayed puberty + short stature + anemia
Your credits are exhausted. Your daily credits reset tomorrow, or you can purchase a top-up for more.
This is a shared conversation. Sign in to Orris to start your own chat.